



## Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025

WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will present a corporate overview at **1:30 PM ET on Monday, April 7, 2025**, at the 24<sup>th</sup> Annual Needham Virtual Healthcare Conference, taking place on April 7–10, 2025.

A live webcast link for the presentation will be available at <https://investors.werewolf.com/news-and-events/events>. An archived replay will be available for approximately 90 days following the event.

### **About Werewolf Therapeutics:**

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR<sup>®</sup> platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf's INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company's most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit [www.werewolf.com](http://www.werewolf.com).

WEREWOLF<sup>®</sup>, the WEREWOLF logo, PREDATOR<sup>®</sup>, INDUKINE<sup>™</sup> and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.

### **Investor Contact**

Dan Ferry  
LifeSci Advisors  
617.430.7576  
daniel@lifesciadvisors.com

### **Media Contact:**

Amanda Sellers  
Deerfield Group  
301.332.5574  
amanda.sellers@deerfieldgroup.com

### **Company Contact:**

Timothy Trost  
Chief Financial Officer  
Werewolf Therapeutics  
ttrost@werewolf.com